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Abstract
Background: Mammographic screening alone will miss a certain fraction of malignancies, as
evidenced by retrospective reviews of mammograms following a subsequent screening.
Mammographic breast density is a marker for increased breast cancer risk and is associated with a
higher risk of interval breast cancer, i.e. cancer detected between screening tests. The purpose of
this review is to estimate risks and benefits of supplemental breast ultrasound in women with
negative mammographic screening with dense breast tissue.
Methods:  A systematic search and review of studies involving mammography and breast
ultrasound for screening of breast cancer was conducted. The search was performed for the period
1/2000-8/2008 within the data source of PubMed, DARE, and Cochrane databases. Inclusion and
exclusion criteria were determined prospectively, and the Oxford evidence classification system
for diagnostic studies was used for evidence level. The parameters biopsy rate, positive predictive
value (PPV) for biopsy, cancer yield for breast ultrasound alone, and carcinoma detection rate by
breast density were extracted or constructed.
Results: The systematic search identified no randomized controlled trials or systematic reviews,
six cohort studies of intermediate level of evidence (3b) were found. Only two of the studies
included adequate follow-up of subjects with negative or benign findings. Supplemental breast
ultrasound after negative mammographic screening permitted diagnosis of primarily invasive
carcinomas in 0.32% of women in breast density type categories 2-4 of the American College of
Radiology (ACR); mean tumor size for those identified was 9.9 mm, 90% with negative lymph node
status. Most detected cancers occurred in mammographically dense breast ACR types 3 and 4.
Biopsy rates were in the range 2.3%-4.7%, with PPV of 8.4-13.7% for those biopsied due to positive
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ultrasound, or about one third of the PPV of biopsies due to mammography. Limitations: The study
populations included wide age ranges, and the application to women age 50-69 years as proposed
for mammographic screening could result in less striking benefit. Further validation studies should
employ a uniform assessment system such as BI-RADS and report not only PPV, but also negative
predictive value, sensitivity and specificity.
Conclusion: Supplemental breast ultrasound in the population of women with mammographically
dense breast tissue (ACR 3 and 4) permits detection of small, otherwise occult, breast cancers.
Potential adverse impacts for women in this intermediate risk group are associated with an
increased biopsy rate.
Background
Up until the early 1990's, breast ultrasound examinations
were primarily used to distinguish between cysts and solid
breast masses and for image-guided, minimally invasive
interventions [1-3], but the diagnostic potential of breast
ultrasound has improved since then. Evolving sono-
graphic technology with high-frequency transducers in
the 7.5-10 MHz range and evolving knowledge has estab-
lished breast ultrasound in the past few years as an imag-
ing procedure to supplement mammography [4-6].
In order to ensure standardized evaluation criteria, the
American College of Radiology (ACR) developed a Breast
Imaging Reporting And Data System (BI-RADS) classifica-
tion for breast ultrasound examinations in 2003 [7],
which is analogous to the BI-RADS classification for mam-
mography [8]. The classification for breast ultrasound (US
BI-RADS) consists of seven categories: 1) negative, 2)
benign, 3) probably benign, 4) suspicious abnormality, 5)
highly suggestive of malignancy, and 6) known malig-
nancy. Category 0 is assigned for results requiring addi-
tional imaging due to limited assessment. Several
international comprehensive quality standards for equip-
ment and staff performing breast ultrasound have adapted
the US BI-RADS criteria [9-12].
International guidelines recommend that breast ultra-
sound be used as a supplemental examination but not as
a primary method for screening of breast cancer [13-17].
Screening for breast cancer focuses on detecting occult
cancer at an early stage with tumor size preferably smaller
than 1 cm, negative lymph node status and with no evi-
dence of distant spread [18]. Mammography has been
established as the primary method for screening. Some
35%-45% of non-palpable cancers are detected as micro-
calcifications in mammographic studies [19]. These
microcalcifications can sometimes be visualized by mod-
ern ultrasound equipment, but cannot be reliably identi-
fied as such without knowledge of mammography
[20,21]. However, not every carcinoma is detected in
breast cancer screening. Breast density is one of the factors
leading to false-negative findings in mammography [22-
25]. Furthermore, mammographically dense breast tissue
has been identified as an independent marker strongly
associated with breast cancer risk and in particular with
higher risk of interval cancer, i.e. cancer detected between
screening tests [26-28]. Epidemiological studies have con-
firmed that individuals at varying risks according to the
appearance of dense breast tissue in mammograms can be
identified, and there is strong evidence for influence by
genetic variants [29,30].
This systematic review examines two issues: First, can a
supplemental breast ultrasound examination performed
as a second-line screening procedure after negative mam-
mography improve the early detection rate of breast can-
cer in asymptomatic women with dense breast tissue?
Second, what potential risks does this involve for the
women examined?
Methods
The aim was to identify studies that provide reliable infor-
mation on the benefit (positive effects of intervention)
and the potential risks (negative effects of intervention) of
supplemental breast ultrasound in breast cancer screen-
ing. The criteria for inclusion or exclusion of studies were
established prospectively before actually running a sys-
tematic search of the literature.
The study populations included asymptomatic primarily
healthy women who took part in mammographic screen-
ing. The evaluation was not limited to women who had
been invited within the framework of an organized mam-
mography screening program.
The value of the intervention 'Doppler sonography of the
breast or axilla' was not included in the questions studied.
Histological confirmation or adequate follow-up were
taken as standards of reference.
The Oxford Classification for diagnostic studies was used,
and publication quality was reported separately when
assessing the studies from a methodological perspective
[31].BMC Cancer 2009, 9:335 http://www.biomedcentral.com/1471-2407/9/335
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Criteria for inclusion and exclusion
In order to ensure evaluability and comparability, the
studies were required to contain the following informa-
tion to be included in the present analysis:
- breast density according to the BI-RADS ACR catego-
ries and/or quantification; ACR 1: almost entirely fat
(low density, up to 25% mammary gland paren-
chyma), ACR 2: scattered fibroglandular densities
(average density, 26-50% gland parenchyma), ACR 3:
heterogeneously dense (high density, 51%-75% gland
parenchyma), ACR 4: extremely dense (very high den-
sity, more than 75% gland parenchyma) [8].
For inclusion, all of the following criteria were required to
be satisfied:
1. study/review deals with the questions under inves-
tigation
2. adequate type of study
3. adequate study population
4. intervention complies with technical standards
(transducer frequency > 5 MHz)
5. required data are provided
Publications were excluded if any of the following criteria
were met:
1. redundancy: multiple publications of the same data
2. methods: case reports, expert opinions, or poor-
quality case-control studies
Literature search
The systematic literature search covered the period from
January 1st, 2000 up to August 30th, 2008 in the following
databases:
1. PubMed (Internet portal of the National Library of
Medicine) http://www.ncbi.nlm.nih.gov/sites/ent
rez?db=pubmed
2. Database of Abstracts of Reviews of Effects (DARE), of
the Centre for Reviews and Dissemination (CRD) http://
www.york.ac.uk/inst/crd/crddatabases.htm#DARE
3. Cochrane-database 'Cochrane Reviews' and 'Clinical
Trials' http://www3.interscience.wiley.com/cgi-bin/
mrwhome/106568753/HOME
The following search words were used:
PubMed: screening AND (mammography OR mammo-
gram) AND breast neoplasms
AND (ultrasonography, mammary OR breast echogra-
phy)
Cochrane und DARE: mammography screening AND
ultrasound
The abstracts found were checked for relevance of content.
Abstracts that did not prove to be relevant were excluded.
Full-text versions of the abstracts deemed to contain rele-
vant information were checked as to the criteria for inclu-
sion and exclusion. The reasons for excluding a full text
were given in each case.
Target values and their definition
Since none of the identified studies addressed the mortal-
ity rate or the difference in mortality rate contributed by
supplemental breast ultrasound, surrogate parameters,
namely the assessment criteria of diagnostic tests, the
additional relative and absolute rates of detected cancers
compared to mammography and tumor size and lymph
node negative status were used as target values. Negative
predictive value, sensitivity and specificity of breast ultra-
sound were only computed if the follow-up period con-
tinued as long as the screening interval, thus permitting
the identification of false-negative findings.
The risk of adverse impacts for the women examined was
quantified using the number of biopsies performed due to
breast ultrasound findings. The positive predictive value
for biopsies with malignant histological findings charac-
terizes the number of unnecessary biopsies induced by
false positives.
Results
The results of the literature search are represented in in
Figure 1. and the details on the excluded studies are pre-
sented in Additional file 1[32-47]. Six cohort studies con-
forming to the inclusion criteria are discussed in detail
(Additional file 2, Part 1; Additional file 3, Part II).
Quality of studies and publications
It could be inferred from the information given in five of
the six studies that women had been enrolled consecu-
tively. The reference standard, i.e. histological confirma-
tion of the findings, was applied in all studies for those
results classified as malignant or suspicious or indetermi-
nate.
Only Kolb et al., 2002 [48] reported a follow-up period of
at least one year (up to the next screening exam) for all
benign, but not for the negative findings. Kaplan, 2001
[49] mentioned a follow-up period for a part of the resultsBMC Cancer 2009, 9:335 http://www.biomedcentral.com/1471-2407/9/335
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Search strategy and search results Figure 1
Search strategy and search results. Flow diagram of search strategy and search results.
Full texts to be obtained
• 1: n = 17
• 2: n =   0
Total:            n  = 17
    Reviews  n =  7
    Individual
           studies     n =  10
Excluded abstracts
•         1: n = 714
•         2: n =   35
•         3: n = 184 
Total:     n = 933
Excluded full texts 
• Reviews       n = 9
• Individual studies    n = 7
-
Total:   n =16
Search (1/1/2000  – 3/2/2007) in Pubmed and Cochrane 
Library  (DARE, Cochrane Reviews,  Cochrane Clinical Trials)
Results : 
1. Pubmed:
[screening AND (mammography OR mammogram)
 AND breast neoplasms AND (ultrasonography, 
mammary OR breast echography)]   n  =  731
2. Cochrane Library :
 [mammography screening AND ultrasound] n =  35
Total:                                n =   766
Included full texts
n = 6
Follow-up search in Pubmed
from 3/3/2007 to 8/30/2008
3. Follow -up search Pubmed:   n = 189
[cf. Search for search items]
Total:                                    n  = 189
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• 3: n =   5
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classified as benign. None of the other studies provided
any information on follow-up.
Due to non-consecutive inclusion of patients and/or an
inconsistently applied reference standard, all studies were
ultimately assigned to the level of evidence category 3b
[31].
As for publication quality, it is worth noting that false pos-
itives were expressed in such a way that the positive pre-
dictive values for ultrasound examination and the biopsy
rate could be calculated in only five of the six studies.
Information on mean or median age was lacking in one
study, while the relative rate of cancers detected by proce-
dures done as a complement to mammography was
reported in five of the six studies.
Group of women examined
The systematic search yielded studies in which breast
ultrasound was used as a supplemental examination fol-
lowing mammographic interpretation. Moreover, of the
group of asymptomatic women with negative mammo-
graphic results, women with breast tissue density (ACR 2-
4) went on to be examined by ultrasound. The only excep-
tion is the study performed by Leconte et al., 2003 [50],
where 3% had palpable findings (Additional file 2, Part I).
The fraction of these women relative to all women
screened within the specified period was reported in two
studies at 36% (Kaplan, 2001 [49]) and 35.8% (Corsetti
et al., 2008 [51]). The size of the study populations ranged
from n = 1517 to n = 13547, with mean n = 5118.
Age distribution
The median age was reported in four studies, ranging from
47.6 years to 60.7 years, with overall age ranges of more
than 30 years in each study. One study provided informa-
tion on mean age (52 years) [51] and one study just
reported age ranges from 35-87 years (Kaplan., 2001
[49]).
Cancer diagnosis according to breast density categories
Two studies analyzed mammographic results of breasts in
categories ACR 3 to ACR 4 [51,49], and the other studies
evaluated the mammograms of ACR 2 to ACR 4 breast tis-
sue [48,50,52,53].
Women with breasts of types ACR 3 or ACR 4 proved to
have the highest proportion of breast cancers diagnosed
by ultrasound screening.
Leconte et al. [50] diagnosed 16 carcinomas in all; 11 of
which were detected in ACR 3 and ACR 4 breast tissue and
five in women with breasts in categories ACR 1 and 2.
Buchberger et al. [53] diagnosed 36 malignancies in breast
tissue of ACR types 3 and 4 (0.3% cancer detection rate
ACR 3, 1.1% cancer detection rate in ACR 4), while two
carcinomas were found in the ACR category 2 breasts
(0.4%). Crystal et al. [52] found no carcinomas in ACR-2
women, and 0.4% and 0.3% in breast-density categories
ACR 3 and ACR 4, respectively. Kaplan [49] diagnosed
cancer at the rate of 0.11% in ACR 2 breast tissue and
0.27% and 0.25% in ACR categories 3 and 4, in the one
series where technologists performed the screening ultra-
sound.
Percentage of carcinomas identified in breast ultrasound
The relative percentage of carcinomas found in supple-
mental breast ultrasound examinations as a fraction of the
total number of detected cancers was reported in four
studies, with a mean percentage of 22.5% (15%-34%)
[53,51,48,50]. The percentage as a fraction of the total
population screened was calculated from all studies, with
a mean value of 0.32% (0.23%-0.41%).
Tumor size and stage (invasive/noninvasive and lymph 
node status)
The mean size of the detected carcinomas was 9.9 mm
(median size range 9.0 mm to 11.0 mm) in five of the six
studies [53,52,49,48,50]. The mean percentage of invasive
cancer detected was 94% (81%-100%) compared to non-
invasive cancer (ductal carcinoma in situ, DCIS) with a
mean of 6% (0%-19%) in all studies. Lymph node status
was reported in four studies with negative lymph nodes in
90% (86%-100%) [51,52,49,48].
Quality of testing
The positive predictive value with regard to the detection
of additional malignancies for ultrasound prompted
biopsies was reported or was able to be inferred from the
given data in four of the six studies. The mean positive
predictive value was 15% (2%-28%) [53,52,49,48]. In
other words, the percentage of positively classified find-
ings for which no carcinoma was subsequently found
ranged from 72% to 98%. This large variation of positive
predictive values can mainly be attributed to the applica-
tion of different sonographic criteria for malignancy and
different assessment categories (see next section). Only
one study reported that all findings classified as benign
were followed up in the interval between two screenings
(Kolb et al., 2002 [48]). However, Kolb et al. [48] do not
mention a follow-up for those patients with negative
results. Kolb states a sensitivity of 75.3%, a specifity of
96.8% and a negative predictive value of 99.7% [48].
Assessment categories for breast ultrasound
The positive predictive value of detecting carcinomas by
breast ultrasound mainly derives from the sonographic
assessment criteria and categories applied. Overall, the
range is still low relative to mammography.BMC Cancer 2009, 9:335 http://www.biomedcentral.com/1471-2407/9/335
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Kaplan, 2001 [49] used a two-armed categorization
approach, namely a simple subdivision into negative and
positive. All positive results were considered to be poten-
tially suspicious. In contrast to the other studies, Kaplan
[49] also deemed cysts positive if they exceeded a size of 1
cm. The author had a low positive predictive value of 2%
[49]. Three studies (Buchberger et al., 2000 [53]; Kolb et
al., 2002 [48] and Leconte et al., 2003 [50]) subdivided
their findings into three categories, but applied different
definitions of these categories. Categories 1, 2 and 3 were
called 'normal', 'benign', and 'suspicious' (Kolb et al.
[48]) or 'benign', 'indeterminate' and 'malignant' (Buch-
berger et al. [53]). These authors found positive predictive
values of biopsy of 10.3% (Kolb et al. [48]) and 28%
(Buchberger et al. [53]). The values for Leconte's study
could not be ascertained [50]. Crystal et al., 2003 [52]
used four arms of classification, thereby reaching a posi-
tive predictive value for malignancy of 20%. Other than
Buchberger et al., Crystal et al. included the 'indetermi-
nate' findings in their calculation of suspicious findings.
Only one study used the five categories proscribed by the
BI-RADS classification for breast ultrasound scans (Cor-
setti et al., 2008 [51]). In this study, however, the positive
predictive value could not be determined.
Rate of biopsies as a result of breast ultrasound
The rate of biopsies resulting from suspicious findings
detected by breast ultrasound ranged from 2.3% (Crystal
et al. [52]) to 4.7% (Corsetti et al., 2008 [51]) as a fraction
of the total population of women screened. The positive
predictive value of biopsies ranged from 8.4% to 13.7%.
The difference compared to the positive predictive value
of the breast ultrasound categorization may be explained
by the fact that biopsies were sometimes also performed
when findings were classified as 'indeterminate'. Clini-
cally speaking, this means that 86.3% up to 91.6% of the
invasive interventions done to confirm the diagnosis did
not lead to a diagnosis of cancer.
Discussion
Methodological aspects
Despite choosing a sensitive search strategy and a very
broad definition of "breast cancer screening", only few
single-center cohort studies analyzing breast ultrasound
in the framework of breast cancer screening could be iden-
tified. All of these studies, however, were planned and
conducted prospectively. The study populations were
characterized by wide age ranges. For this reason, the
results cannot be directly applied to women asked to par-
ticipate in an organized population-based mammography
screening program while aged between 50 and 69 years.
Since the studies applied different assessment criteria and
classifications with regard to ultrasound morphology,
their results are comparable only to a limited extent. As
most studies lacked the requisite follow-up needed for
computing sensitivity, specificity and negative predictive
value, a comprehensive appraisal of the test quality of the
intervention breast ultrasound could not be undertaken.
None of the studies of US in breast screening were RCTs;
therefore studies were not designed to provide evidence
on screening benefit in terms of mortality reduction.
Discussion of content
The effectiveness of breast ultrasound as a screening tool
was mainly studied in women with breast tissue of the cat-
egories ACR 2 to ACR 4 and invariably only after previous
mammography screening had yielded a negative result.
Women with dense breasts run a four- to six-fold higher
risk of developing breast cancer than other women
[26,27]. The results revealed that supplemental breast
ultrasound after negative mammographic screening per-
mits the diagnosis of primarily invasive carcinomas in this
risk group of women in an absolute mean of 0.32% of the
cases. For comparative purposes: In population-based
screening using mammography alone a mean of 0.4%-
0.9% of all women screened were diagnosed with cancer
[54].
The majority of cancers were detected in breast tissue of
ACR types 3 and 4. According to these studies, the mean
size of the cancers diagnosed additionally by breast ultra-
sound was not larger than the size of those visualized in
mammography screening.
Berg (2004 [39]) reported similar results in a review of the
application of breast ultrasound in women with dense
breasts. The review was excluded because no systematic
search strategy was specified, but Berg analyzed five of the
six studies identified (Buchberger et al. [53]; Kaplan [49];
Kolb et al. [48]; Crystal et al. [52]; and Leconte et al. [50])
and, in addition, a study by Gordon et al., 1995 [55]. She
calculated a pooled value for the additional detection of
cancers in the study populations of 0.35% and reported
that 94% of the cancers detected in breast ultrasound were
invasive with a mean diameter of 9-11 mm [39]. More
than 90% of the women in whom cancer was detected by
breast ultrasound had breast density corresponding to
ACR categories 3 or 4 [39].
Hence, the contribution of supplemental breast ultra-
sound for the detection of breast cancer is primarily rele-
vant for women with ACR 3 or ACR 4 tissue density. The
question of whether improved detection of carcinomas
leads to decreased breast cancer mortality cannot be
answered on the basis of the available studies, although
mathematical models allow to relate tumor size, lymph
node involvement and death rates [18,56,57].
Concerning possible adverse impacts of additional breast
ultrasound, the biopsy rates in the evaluated studies of
2.3%-4.7% were significantly higher than the biopsy ratesBMC Cancer 2009, 9:335 http://www.biomedcentral.com/1471-2407/9/335
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of about 1%-2% resulting from mammographic screen-
ings [58-60]. Moreover, the positive predictive value of
biopsies (mean 10.3%) was significantly lower than that
of mammography screening (mean approximately 38%)
[59-61], i.e. three times more women need to undergo a
biopsy per carcinoma detected. Although findings visual-
ized by ultrasound examination can easily be biopsied in
a minimally-invasive procedure, risk assessment should
still take into consideration the psychological strain that
women experience before and during biopsy performed
because of a false-positive ultrasound result [62,63].
The heterogeneous nature of the assessment criteria for
breast ultrasound examinations, which in turn influence
biopsy rates, is quite striking. Due to this heterogeneity,
comparability of the studies is limited, and the effect of
differences in experience of examiners is difficult to quan-
tify. Since few studies included adequate follow-up of sub-
jects with negative or benign findings, the false-negative
rate in women with high breast density -- and hence the
proportion of cancers missed by mammography and also
missed by the addition of breast ultrasound in this group
-- cannot be reliably estimated.
In 2003, Berg [61] initiated a prospective multicenter trial,
randomized to the sequence of performance of mammog-
raphy and ultrasound in women with intermediate and
high breast cancer risk. Adding a single screening ultra-
sound to mammography yielded additional 1.1 to 7.2
cancers per 1000 high-risk women, but also substantially
increased the number of false positives [37]. The study
provided evidence for the importance of supplemental
breast ultrasound screening. Furthrmore the standardized
scanning and interpretive criteria proved to be practicable
for independent performance and intrepretation and
could be used for further implementation. However, in
view of the selected study cohort the results cannot be
applied directly to a population-based screening program
for asymptomatic women aged 50-69 years without per-
sonal history evaluation prior performing mammogra-
phy.
Conclusion
As far as the transferability of the findings to a population-
based mamographic screening program for women aged
50-69 years as currently practiced in many countries is
concerned, one can conclude the following:
1. The reviewed studies provided limited evidence that
within the framework of screening for breast cancer,
an additional ultrasound examination after a negative
mammogram is useful for the detection of primarily
invasive cancers in women with mammographically
dense breast tissue (ACR types 3 and 4, with more than
50% parenchymal gland), with the mean size of inva-
sive cancers thus identified being 9.9 mm and in 90%
with negative lymph node status.
2. As for adverse impacts resulting from the breast
ultrasound intervention, three times more women
need to undergo a biopsy per carcinoma detected by
supplemental ultrasound compared to cancers
detected by mammography screening alone.
3. Since the study populations were characterized by
very broad age ranges and invariably also included
younger women, the impact in an organized popula-
tion-based mammography screening program, includ-
ing only women in the age group of 50 to 69 years,
could be reduced.
4. There is a need for prospective validating studies of
risk-adjusted, second-line, supplemental breast ultra-
sound screening in women with dense breast tissue
(ACR types 3 and 4), performed within the framework
of established population-based mammography-
screening-programs.
5. Validating studies should not only state the positive
predictive value, but also the sensitivity, specificity
and negative predictive value for breast ultrasound.
Quality of performance standards and a uniform
assessment system, such as the ultrasound BI-RADS™
categories, should be applied, so that the precise rea-
sons for the biopsies can be given and explained accu-
rately.
6. In analogy to the quality assurance assessments of
established mammography screening programs, per-
formance indicators and surrogate end points, such as
tumor size, lymph node status are effective and accu-
rate, and should be used for health care outcomes
analyses. Beside lethality, issues such as quality of life
and health care costs are of importance.
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